HANGZHOU, China--(BUSINESS WIRE)--Hangzhou Qihan Biotech Co., Ltd. ('Qihan' or 'Qihan Biotech' or 'the Company'), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Yingyong Xu as the Chief Medical Officer..

中国杭州——（商业新闻短讯）——杭州奇翰生物技术有限公司（“奇翰”或“奇翰生物技术”或“该公司”）是将多重基因组编辑技术应用于细胞疗法和器官移植的行业领导者，今天宣布任命徐英勇先生为首席医疗官。。

Mr. Yingyong Xu brings over two decades of specialized expertise in clinical treatment and innovative drug development in hematology and oncology. He has participated in the development of new drugs for chronic myeloid leukemia, lymphoma, myeloma, myelodysplastic syndrome, lung cancer, pancreatic cancer, and more.

徐英勇先生在血液学和肿瘤学的临床治疗和创新药物开发方面拥有20多年的专业知识。他参与了慢性粒细胞白血病、淋巴瘤、骨髓瘤、骨髓增生异常综合征、肺癌、胰腺癌等新药的开发。

Before joining Qihan Biotech, Mr. Xu served as Vice President of Clinical at Zai lab, where he led product development initiatives, focusing on hematologic malignancies and lung cancer for over four years. Prior to Zai lab, he worked at Bristol Myers Squibb and Celgene and concentrated his efforts on clinical product development in hematologic malignancies and pancreatic cancer.

在加入齐汉生物科技之前，徐先生曾担任Zai lab临床副总裁，在那里他领导产品开发计划，专注于血液系统恶性肿瘤和肺癌超过四年。在加入Zai实验室之前，他曾在百时美施贵宝和Celgene工作，并专注于血液恶性肿瘤和胰腺癌的临床产品开发。

Before transitioning to the pharmaceutical industry in 2011, Mr. Xu was a pediatric hematologist-oncologist specializing in allogeneic hematopoietic stem cell transplantation..

在2011年转入制药行业之前，徐先生是一名儿科血液病肿瘤学家，专门从事异基因造血干细胞移植。。

Mr. Xu earned his master's degree from Shanghai Jiao Tong University School of Medicine, where he researched allogeneic hematopoietic stem cell transplantation for refractory childhood leukemia. He is currently pursuing a Doctor of Management degree at Manchester Business School, University of Manchester, focusing his research on the ecosystem of drug innovation..

徐先生在上海交通大学医学院获得硕士学位，研究异基因造血干细胞移植治疗难治性儿童白血病。他目前正在曼彻斯特大学曼彻斯特商学院攻读管理博士学位，专注于药物创新生态系统的研究。。

Dr. Luhan Yang, Founder and CEO of Qihan Biotech, stated, 'We are delighted to welcome Mr. Yingyong Xu to Qihan. His extensive experience in clinical translation and corporate management will undoubtedly bolster our clinical operations and drive the development of high-quality cell therapy drugs that can significantly benefit patients.'.

齐汉生物科技创始人兼首席执行官杨鲁汉博士表示，“我们很高兴欢迎徐英勇先生来到齐汉。他在临床翻译和企业管理方面的丰富经验无疑将支持我们的临床运营，并推动高质量细胞治疗药物的开发，从而使患者受益匪浅。”。

'I am pleased to join Qihan and have great confidence in its platform and team. My background as a physician motivates me to contribute to cell therapy. Under the leadership of Dr. Luhan Yang, the Qihan team will bring revolutionary treatment modalities to patients', Mr. Xu said.

“我很高兴加入奇翰，对其平台和团队充满信心。我作为医生的背景激励我为细胞疗法做出贡献。徐先生说，在杨鲁汉博士的领导下，齐汉团队将为患者带来革命性的治疗方式。

About Qihan Biotech

关于奇翰生物科技

Qihan Biotech is a biotechnology company applying genome editing technology to develop novel cell therapies and organs for transplantation. The company's mission is to use high-throughput, multiplexable genome editing combined with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, autoimmune diseases, organ failure, and other complex medical conditions.

齐汉生物科技是一家应用基因组编辑技术开发新型细胞疗法和器官移植的生物技术公司。该公司的使命是利用高通量、可多重扩增的基因组编辑技术，结合移植免疫学的专业知识，创建具有免疫特权的同种异体细胞和异种器官，用作治疗癌症、自身免疫性疾病、器官衰竭和其他复杂疾病的疗法。

With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised two financing rounds. It has multiple products at different stages of development, including QN-019a, which had already received IND approval from China NMPA to treat CD19-positive relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

齐汉生物科技公司（QihanBiotech）已经发起了两轮融资，旨在创造一个细胞和器官疗法普遍适用于患者的世界。它在不同的开发阶段拥有多种产品，包括QN-019a，该产品已获得中国NMPA的IND批准，用于治疗CD19阳性复发/难治性侵袭性B细胞非霍奇金淋巴瘤。

Qihan's deep scientific experience and technology advancements have enabled the company to create cutting-edge cell therapy products. Qihan Biotech is headquartered in Hangzhou, China. For more information, please visit the company's website at www.qihanbio.com..

齐汉深厚的科学经验和技术进步使公司能够创造出尖端的细胞疗法产品。奇翰生物科技总部位于中国杭州。欲了解更多信息，请访问公司网站www.qihanbio.com。。

Forward-looking Statements

前瞻性声明

This release contains statements including, but not limited to, Qihan’s research development and/or relevant programs, its past, ongoing, and planned research studies, and the potential of Qihan’s research candidate. These and any other statements in this release are based on Qihan management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such statements.

本版本包含声明，包括但不限于齐汉的研究发展和/或相关计划，其过去，正在进行和计划进行的研究，以及齐汉研究候选人的潜力。本新闻稿中的这些和任何其他声明均基于齐汉管理层目前对未来事件的预期，并受到许多风险和不确定性的影响，这些风险和不确定性可能导致实际结果与此类声明中规定或暗示的结果产生重大不利影响。

These risks and uncertainties include, but are not limited to, the risk that Qihan’s research program may not warrant further development, the risk that results observed in prior studies of Qihan’s research candidates will not be observed in ongoing or future studies involving these candidates, the risk of a delay or difficulties in the developing or transforming of Qihan’s research candidates, the risk that Qihan may cease or delay the research development of any of its candidates for a variety of reasons.

这些风险和不确定性包括但不限于，齐汉的研究计划可能不值得进一步发展的风险，齐汉研究候选人先前研究中观察到的结果在涉及这些候选人的正在进行或未来研究中不会被观察到的风险，齐汉研究候选人发展或转化过程中出现延迟或困难的风险，齐汉可能因各种原因停止或延迟任何候选人的研究发展的风险。

Qihan is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in this release as a result of new information, future events, or otherwise. Information concerning therapies and related products contained herein is not intended as medical advice..

Qihan在本版本中提供截至该日期的信息，不承担因新信息、未来事件或其他原因而更新本版本中包含的任何声明的任何义务。此处包含的有关治疗和相关产品的信息不作为医疗建议。。

Source: Hangzhou Qihan Biotech Co., Ltd.

资料来源：杭州奇翰生物科技有限公司。